Chemical Reviews pubs.acs.
org/CR Review
Desirable Mechanistic and Pre-Clinical DMPK Attributes. Cancer Res. Mutant Lung Cancers: Results From a Phase II Basket Trial. J. Clin.
2019, 79, P5-04-07. Oncol. 2018, 36, 2532−2537.
(301) Bardia, A.; Linden, H. M.; Ulaner, G. A.; Chandarlapaty, S.; (317) Tsurutani, J.; Park, H.; Doi, T.; Modi, S.; Takahashi, S.;
Gosselin, A.; Doroumian, S.; Celanovic, M.; Campone, M. Dose- Nakagawa, K.; Krop, I.; Waqar, S.; Yoh, K.; Li, B.; et al. Updated
Escalation Study of SAR439859, an Oral Selective Estrogen Receptor Results of Phase 1 Study of DS-8201a in HER2-Expressing or −
(ER) Degrader (SERD), in Postmenopausal Women with ER Mutated Advanced Non-Small-Cell Lung Cancer. J. Thorac. Oncol.
+/HER2- Metastatic Breast Cancer (mBC). J. Clin. Oncol. 2019, 37, 2018, 13, S324.
1054. (318) Morin-Ben Abdallah, S.; Wong, A. Brain Metastases in Non-
(302) Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y.-S.; Duhoux, F. P.; Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and
Terret, C.; Layman, R.; Kundamal, N.; Liao, S.; Ji, Y. A phase 1/1b Checkpoint Inhibitors Now Viable Options? Curr. Oncol 2018, 25,
study of LSZ102, an oral selective estrogen receptor degrader S103−S114.
(SERD), in combination with ribociclib in patients with estrogen (319) Kancha, R. K.; von Bubnoff, N.; Bartosch, N.; Peschel, C.;
receptor-positive (ER+) advanced breast cancer (ABC) who had Engh, R. A.; Duyster, J. Differential Sensitivity of ERBB2 Kinase
progressed after endocrine therapy (ET). Cancer Res. 2020, 80, PD7- Domain Mutations Towards Lapatinib. PLoS One 2011, 6, e26760.
09. (320) Hanker, A. B.; Brewer, M. R.; Sheehan, J. H.; Koch, J. P.;
(303) Wang, L.; Guillen, V. S.; Sharma, N.; Flessa, K.; Min, J.; Sliwoski, G. R.; Nagy, R.; Lanman, R.; Berger, M. F.; Hyman, D. M.;
Carlson, K. E.; Toy, W.; Braqi, S.; Katzenellenbogen, B. S.; Solit, D. B.; et al. An Acquired HER2T798I Gatekeeper Mutation
Katzenellenbogen, J. A.; et al. New Class of Selective Estrogen Induces Resistance to Neratinib in a Patient with HER2Mutant−
Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Driven Breast Cancer. Cancer Discovery 2017, 7, 575−585.
Degrons. ACS Med. Chem. Lett. 2018, 9, 803−808. (321) Meric-Bernstam, F.; Beeram, M.; Mayordomo, J. I.; Hanna, D.
(304) Scheepstra, M.; Hekking, K. F. W.; van Hijfte, L.; Folmer, R. L.; Ajani, J. A.; Blum Murphy, M. A.; Murthy, R. K.; Piha-Paul, S. A.;
H. A. Bivalent Ligands for Protein Degradation in Drug Discovery. Bauer, T. M.; Bendell, J. C.; et al. Single Agent Activity of ZW25, a
Comput. Struct. Biotechnol. J. 2019, 17, 160−176. HER2-Targeted Bispecific Antibody, in Heavily Pretreated HER2-
(305) Meric-Bernstam, F.; Johnson, A. M.; Dumbrava, E. E. I.; Expressing Cancers. J. Clin. Oncol. 2018, 36, 2500.
Raghav, K.; Balaji, K.; Bhatt, M.; Murthy, R. K.; Rodon, J.; Piha-Paul, (322) Baird, R.; Omlin, A.; Kiemle-Kallee, J.; Fiedler, U.; Zitt, C.;
S. A. Advances in HER2-Targeted Therapy: Novel Agents and Feurstein, D.; Herbst, J.; Dawson, K.; vom Baur, E.; Stumpp, M.; et al.
Opportunities Beyond Breast and Gastric Cancer. Clin. Cancer Res. MP0274-CP101: A Phase 1, First-In-Human, Single-Arm, Multi-
2019, 25 (7), 2033−2041. Center, Open-Label, Dose Escalation Study to Assess Safety,
(306) Gajria, D.; Chandarlapaty, S. HER2-Amplified Breast Cancer: Tolerability, and Pharmacokinetics of MP0274 in Patients with
Mechanisms of Trastuzumab Resistance and Novel Targeted Advanced HER2-Positive Solid Tumors. Cancer Res. 2018, 78, OT1-
Therapies. Expert Rev. Anticancer Ther. 2011, 11, 263−275.
03-02.
(307) FDA Approves Trastuzumab Biosimilar. Cancer Discovery
(323) Murthy, R. K.; Loi, S.; Okines, A.; Paplomata, E.; Hamilton,
2018, 8, 130.2..
E.; Hurvitz, S. A.; Lin, N. U.; Borges, V.; Abramson, V.; Anders, C.;
(308) Chen, S.; Liang, Y.; Feng, Z.; Wang, M. Efficacy and Safety of
et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive
HER2 Inhibitors in Combination With or Without Pertuzumab for
Metastatic Breast Cancer. N. Engl. J. Med. 2020, 382, 597−609.
HER2-Positive Breast Cancer: A Systematic Review and Meta-
(324) Dang, L.; White, D. W.; Gross, S.; Bennett, B. D.; Bittinger, M.
Analysis. BMC Cancer 2019, 19, 973.
A.; Driggers, E. M.; Fantin, V. R.; Jang, H. G.; Jin, S.; Keenan, M. C.;
(309) Nakada, T.; Sugihara, K.; Jikoh, T.; Abe, Y.; Agatsuma, T. The
Latest Research and Development into the Antibody−Drug et al. Cancer-Associated IDH1Mutations Produce 2-Hydroxygluta-
Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 rate. Nature 2009, 462, 739−744.
Cancer Therapy. Chem. Pharm. Bull. 2019, 67, 173−185. (325) Popovici-Muller, J.; Lemieux, R. M.; Artin, E.; Saunders, J. O.;
(310) Rinnerthaler, G.; Gampenrieder, S. P.; Greil, R. HER2 Salituro, F. G.; Travins, J.; Cianchetta, G.; Cai, Z.; Zhou, D.; Cui, D.;
Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant
Cancer. Int. J. Mol. Sci. 2019, 20, 1115−1132. IDH1 Inhibitor for the Treatment of IDH1Mutant Cancers. ACS
(311) Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, Med. Chem. Lett. 2018, 9, 300−305.
K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, (326) Yen, K.; Travins, J.; Wang, F.; David, M. D.; Artin, E.; Straley,
R. J.; et al. The Effects of the Novel, Reversible Epidermal Growth K.; Padyana, A.; Gross, S.; DeLaBarre, B.; Tobin, E.; et al. AG-221, a
Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring
Growth of Human Normal and Tumor-Derived Cell Lines In Vitro Oncogenic IDH2Mutations. Cancer Discovery 2017, 7, 478−493.
and In Vivo. Mol. Cancer Ther. 2001, 1, 85−94. (327) Intlekofer, A. M.; Shih, A. H.; Wang, B.; Nazir, A.;
(312) Tsang, R. Y.; Sadeghi, S.; Finn, R. S. Lapatinib, a Dual- Rustenburg, A. S.; Albanese, S. K.; Patel, M.; Famulare, C.; Correa,
Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2- F. M.; Takemoto, N.; et al. Acquired Resistance to IDH Inhibition
Amplified Breast Cancer: From Bench to Bedside. Clin. Med. Insights: Through Trans or Cis Dimer-Interface Mutations. Nature 2018, 559,
Ther. 2011, 3, CMT.S3783. 125−129.
(313) Tonge, P. J. Drug-Target Kinetics in Drug Discovery. ACS (328) Harding, J. J.; Lowery, M. A.; Shih, A. H.; Schvartzman, J. M.;
Chem. Neurosci. 2018, 9, 29−39. Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R. K.; Zehir, A.;
(314) Xia, W.; Mullin, R. J.; Keith, B. R.; Liu, L.-H.; Ma, H.; Rusnak, et al. Isoform Switching as a Mechanism of Acquired Resistance to
D. W.; Owens, G.; Alligood, K. J.; Spector, N. L.; et al. Anti-tumor Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery 2018,
Activity of GW572016: A Dual Tyrosine Kinase Inhibitor Blocks EGF 8, 1540−1547.
Activation of EGFR/erbB2 and Downstream Erk1/2 and AKT (329) Golub, D.; Iyengar, N.; Dogra, S.; Wong, T.; Bready, D.;
Pathways. Oncogene 2002, 21, 6255−63. Tang, K.; Modrek, A. S.; Placantonakis, D. G. Mutant Isocitrate
(315) Mazieres, J.; Peters, S.; Lepage, B.; Cortot, A. B.; Barlesi, F.; Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Front.
Beau-Faller, M.; Besse, B.; Blons, H.; Mansuet-Lupo, A.; Urban, T.; Oncol. 2019, 9, 417.
et al. Lung Cancer that Harbors an HER2Mutation: Epidemiologic (330) Ma, R.; Yun, C. H. Crystal structures of pan-IDH inhibitor
Characteristics and Therapeutic Perspectives. J. Clin. Oncol. 2013, 31, AG-881 in complex with mutant human IDH1 and IDH2. Biochem.
1997−2003. Biophys. Res. Commun. 2018, 503, 2912−2917.
(316) Li, B. T.; Shen, R.; Buonocore, D.; Olah, Z. T.; Ni, A.; (331) Cho, Y. S.; Levell, J. R.; Liu, G.; Caferro, T.; Sutton, J.; Shafer,
Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, C. M.; Costales, A.; Manning, J. R.; Zhao, Q.; Sendzik, M.; et al.
T.; et al. Ado-Trastuzumab Emtansine for Patients With HER2- Discovery and Evaluation of Clinical Candidate IDH305, a Brain
BA https://dx.doi.org/10.1021/acs.chemrev.0c00383
Chem. Rev. XXXX, XXX, XXX−XXX
